Correction: Corrigendum: MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool

Addiction to MTH1 protein results in intense expression in human breast cancer tissue as measured by liquid chromatography-isotope-dilution tandem mass spectrometry

“…This observation is on a par with the highly significant expression of hMTH1 in MCF-7 adenocarcinoma cells when compared with MCF-10A normal cells of the same origin. Our findings are in agreement with those showing that MTH1 is overexpressed in many cancers [23,24,30,31]. Furthermore, MTH1 expression has been found to be strongly correlated with upregulated RAS, as cancers with high prevalence of ras mutations such as lung and colon cancers have been found to express greater levels of MTH1 than other unrelated cancers [30,31].…”

“…Our findings are in agreement with those showing that MTH1 is overexpressed in many cancers [23,24,30,31]. Furthermore, MTH1 expression has been found to be strongly correlated with upregulated RAS, as cancers with high prevalence of ras mutations such as lung and colon cancers have been found to express greater levels of MTH1 than other unrelated cancers [30,31]. However, all cancers are not equal, and expression of MTH1 strongly differs between cancers [30,31].…”

“…Recent studies showed that hMTH1 is an excellent target for inhibition in cancer therapy [30,31]. Since hMTH1 is overexpressed in many cancers, and its activity markedly increased [23][24][25]30,31], the level of its expression may affect cancer phenotype and response of various tumors to conventional treatments and to future combination therapies using inhibitors of hMTH1 as drugs.…”

“…Since hMTH1 is overexpressed in many cancers, and its activity markedly increased [23][24][25]30,31], the level of its expression may affect cancer phenotype and response of various tumors to conventional treatments and to future combination therapies using inhibitors of hMTH1 as drugs. Many treatments target the genetic defects found in cancers; however, the diversity and complexity of mutational processes underlying the development of cancer may have potential implications for therapy and limit targeting genetic defects in future personalized therapies [40].…”

“…MTH1 appears to be a non-essential protein in normal cells by the fact that no significant difference was observed in the survival rate of wild type and mth1 −/− mice, although more tumors were found in aged mth1 −/− mice than in wild type mice [18]. On the other hand, cancer cells have been shown to require MTH1 for efficient survival by preventing the incorporation of modified dNTPs that would result in DNA damage and cell death, suggesting that this protein may be targeted as an anticancer therapeutic approach [30,31]. Thus, this work validated MTH1 as an anticancer target in vivo and showed that the inhibition of MTH1 by small molecules as first-in-class Nudix hydrolase family inhibitors eradicates cancer in patient-derived mouse xenografts.…”